Paraplegia News and Research

RSS
Paraplegia is an impairment in motor or sensory function of the lower extremities. It is usually the result of spinal cord injury or a congenital condition such as spina bifida which affects the neural elements of the spinal canal.
Simvastatin may reduce spinal cord damage from ischemia/reperfusion injury

Simvastatin may reduce spinal cord damage from ischemia/reperfusion injury

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Scientists probe 'atlastin,' a protein linked to hereditary spastic paraplegia

Scientists probe 'atlastin,' a protein linked to hereditary spastic paraplegia

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Relay stent-graft safe and effective for patients with aortic dissections

Relay stent-graft safe and effective for patients with aortic dissections

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Researchers investigate why immune system is blunted after spinal cord injury

Researchers investigate why immune system is blunted after spinal cord injury

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Tip sheets provide details on hip and knee fracture treatment

Tip sheets provide details on hip and knee fracture treatment

Role of hybrid Brain Computer Interface in people with paraplegia

Role of hybrid Brain Computer Interface in people with paraplegia

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

Neuralstem ends litigation with ReNeuron

Neuralstem ends litigation with ReNeuron

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

FDA approves BOTOX as prophylactic treatment for Chronic Migraine